Clinical pharmacology of comorbid obsessive-compulsive disorder in tourette syndrome

International Review of Neurobiology

Volumn 112, Issue , 2013, Pages 391-414

  Neri, Valeria ^a   Cardona, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Augmentation; Monotherapy; OCD; Resistance; Safety; SRI SSRI; Tourette Syndrome; Treatment

Indexed keywords

ACETYLCYSTEINE; AMANTADINE; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; CYCLOSERINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MEMANTINE; MORPHINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE;

ARTICLE; BEHAVIOR THERAPY; BLURRED VISION; CLINICAL PHARMACOLOGY; COGNITIVE THERAPY; COMORBIDITY; CONSCIOUSNESS; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INSOMNIA; MONOTHERAPY; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHODYNAMICS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SEIZURE; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

AUGMENTATION; MONOTHERAPY; OCD; RESISTANCE; SAFETY; SRI/SSRI; TOURETTE SYNDROME; TREATMENT;

COMORBIDITY; DATABASES, BIBLIOGRAPHIC; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PHARMACOLOGY, CLINICAL; TOURETTE SYNDROME;

EID: 84888396924     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411546-0.00013-5     Document Type: Chapter

References (87)

1. American Psychiatric Association Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Journal of Psychiatry 2007, 164(Suppl.):1-56.
2. Ansorge M.S., Morelli E., Gingrich J.A. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. Journal of Neuroscience 2008, 28(1):199-207.
3. Arnold P.D., Sicard T., Burroughs E., Richter M.A., Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Archives of General Psychiatry 2006, 63(7):769-776.
4. Barbey J.T., Roose S.P. SSRI safety in overdose. Journal of Clinical Psychiatry 1998, 59(Suppl. 15):42-48.
5. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S., et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 2011, 72(5):716-721.
6. Bhattacharyya S., Chakraborty K. Glutamatergic dysfunction-Newer targets for anti-obsessional drugs. Recent Patents on CNS Drug Discovery 2007, 2(1):47-55.
7. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., Leckman J.F. A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11(7):622-632.
8. Bloch M.H., Leckman J.F. Clinical course of Tourette syndrome. Journal of Psychosomatic Research 2009, 67(6):497-501.
9. Bloch M.H., McGuire J., Landeros-Weisenberger A., Leckman J.F., Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2010, 15(8):850-855.
10. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. The Journal of the American Medical Association 2007, 297(15):1683-1696.
11. Bystritsky A., Ackerman D.L., Rosen R.M., Vapnik T., Gorbis E., Maidment K.M., et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. Journal of Clinical Psychiatry 2004, 65(4):565-568.
12. Carey P.D., Vythilingum B., Seedat S., Muller J.E., van Ameringen M., Stein D.J. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 2005, 5:5.
13. Cavanna A.E., Servo S., Monaco F., Robertson M.M. The behavioral spectrum of Gilles de la Tourette syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences 2009, 21(1):13-23.
14. Chasson G.S., Buhlmann U., Tolin D.F., Rao S.R., Reese H.E., Rowley T., et al. Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behaviour Research and Therapy 2010, 48:675-679.
15. Day L., Gorman D., Pringsheim T. Pharmacotherapy of obsessive-compulsive disorder in individuals with co-morbid tic disorders. Canadian guidelines for the evidence-based treatment of tourette syndrome 2012, 97-107. Tourette Syndrome Foundation of Canada - Mississauga, Ontario - Canada. T. Pringsheim (Ed.).
16. Debes N.M., Hjalgrim H., Skov L. The presence of comorbidity in Tourette syndrome increases the need for pharmacological treatment. Journal of Child Neurology 2009, 24(12):1504-1512.
17. Decloedt E.H., Stein D.J. Current trends in drug treatment of obsessive-compulsive disorder. Journal of Neuropsychiatric Disease and Treatment 2010, 6:233-242.
18. Denys D., de Geus F., van Megen H.J., Westenberg H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry 2004, 65(8):1040-1048.
19. Dold M., Aigner M., Lanzenberger R., Kasper S. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder-A meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschritte der Neurologie-Psychiatrie 2011, 79(8):453-466.
20. Eapen V., Robertson M.M., Alsobrook J.P., Pauls D.L. Obsessive-compulsive symptoms in Gilles de la Tourette syndrome and obsessive compulsive disorder. American Journal of Medical Genetics 1997, 74(4):432-438.
21. Eddy K.T., Dutra L., Bradley R., Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clinical Psychology Review 2004, 24:1011-1030.
22. Eddy C.M., Rickards H.E., Cavanna A.E. Treatment strategies for tics in Tourette syndrome. Therapeutic Advances in Neurological Disorders 2011, 4(1):25-45.
23. Erzegovesi S., Guglielmo E., Siliprandi F., Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: A double-blind, placebo-controlled study. European Neuropsychopharmacology 2005, 15(1):69-74.
24. Fernandez-Cordoba E., Lopez-Ibor Alino J. Monochlorimipramine in mental patients resisting other forms of treatment. Actas luso-espanolas de neurologia y psiquiatria 1967, 26:119-147.
25. Fineberg N.A., Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. The International Journal of Neuropsychopharmacology 2005, 8(1):107-129.
26. Foa E.B. Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues in Clinical Neuroscience 2010, 12(2):199-207.
27. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo- controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. The American Journal of Psychiatry 2005, 162:151-161.
28. Frankel M., Cummings J.L., Robertson M.M., Trimble M.R., Hill M.A., Benson D.F. Obsessions and compulsions in Gilles de la Tourette's syndrome. Neurology 1986, 36(3):378-382.
29. Franklin M.E., Abramowitz J.S., Kozak M.J., Levitt J.T., Foa E.B. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: Randomized compared with nonrandomized samples. Journal of Consulting and Clinical Psychology 2000, 68:594-602.
30. Freeman R.D., Fast D.K., Burd L., Kerbeshian J., Robertson M.M., Sandor P. An international perspective on Tourette syndrome: Selected findings from 3500 individuals in 22 countries. Developmental Medicine and Child Neurology 2000, 42:436-447.
31. Geller D.A., Biederman J., Stewart S.E., Mullin B., Martin A., Spencer T., et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. The American Journal of Psychiatry 2003, 160(11):1919-1928.
32. George M.S., Trimble M.R., Ring H.A., Sallee F.R., Robertson M.M. Obsessions in obsessive-compulsive disorder with and without Gilles de la Tourette's syndrome. The American Journal of Psychiatry 1993, 150(1):93-97.
33. Gilbert D. Treatment of children and adolescents with tics and Tourette syndrome. Journal of Child Neurology 2006, 21(8):690-700.
34. Goodman W.K., Storch E.A., Geffken G.R., Murphy T.K. Obsessive-compulsive disorder in Tourette syndrome. Journal of Child Neurology 2006, 21(8):704-714.
35. Hollander E., Baldini Rossi N., Sood E., Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. The International Journal of Neuropsychopharmacology 2003, 6(4):397-401.
36. Holzer J.C., Goodman W.K., McDougle C.J., Baer L., Boyarsky B.K., Leckman J.F., et al. Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. The British Journal of Psychiatry 1994, 164(4):469-473.
37. Husted D.S., Shapira N.A., Murphy T.K., Mann G.D., Ward H.E., Goodman W.K. Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder. Journal of Psychiatric Research 2007, 41(3-4):332-337.
38. Ipser J.C., Carey P., Dhansay Y., Fakier N., Seedat S., Stein D.J. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database of Systematic Reviews 2006, (4). CD005473. 10.1002/14651858.CD005473.pub2.
39. Jaisoorya T.S., Reddy Y.C., Srinath S., Thennarasu K. Obsessive-compulsive disorder with and without tic disorder: A comparative study from India. CNS Spectrum 2008, 13(8):705-711.
40. Jankovic J., Kurlan R. Tourette syndrome: Evolving concepts. Movement Disorders 2011, 26(6):1149-1156.
41. Jenike M.A. Treating obsessive-compulsive disorder. Harvard Mental Health Letter 2009, 25:4-5.
42. Khalifa N., Von Knorring A.L. Psychopathology in a Swedish population of school children with tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45(11):1346-1353.
43. Koran L.M., Aboujaoude E., Bullock K.D., Franz B., Gamel N., Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 2005, 66(3):353-359.
44. Koran L.M., Aboujaoude E., Gamel N.N. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 2009, 70(11):1530-1535.
45. Leckman J.F., Grice D.E., Barr L.C., deVries A.L.C., Martin C., Cohen D.J., et al. Tic-related vs. non-tic related obsessive compulsive disorder. Anxiety 1995, 1:208-215.
46. Ludolph A.G., Roessner V., Münchau A., Müller-Vahl K. Tourette syndrome and other tic disorders in childhood, adolescence and adulthood. Deutsches Ärzteblatt International 2012, 109(48):821-828.
47. Maina G., Albert U., Salvi V., Bogetto F. Weight gain during long- term treatment of obsessive-compulsive disorder: A prospective comparison between serotonin reuptake inhibitors. Journal of Clinical Psychiatry 2004, 65(10):1365-1371.
48. Mancuso E., Faro A., Joshi G., Geller D.A. Treatment of pediatric obsessive-compulsive disorder: A review. Journal of Child and Adolescent Psychopharmacology 2010, 20(4):299-308.
49. March J.S., Franklin M.E., Leonard H., Garcia A., Moore P., Freeman J., et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry 2007, 61(3):344-347.
50. Martin A., Young C., Leckman J.F., Mukonoweshuro C., Rosenheck R., Leslie D. Age effects on antidepressant-induced manic conversion. Archives of Pediatrics and Adolescent Medicine 2004, 158(8):773-780.
51. McDougle C.J., Epperson C.N., Pelton G.H., Wasylink S., Price L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry 2000, 57(8):794-801.
52. McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry 1994, 51(4):302-308.
53. Meyer V. Modification of expectations in cases with obsessional rituals. Behaviour Research and Therapy 1966, 4:273-280.
54. Miguel E.C., Baer L., Coffey B.J., Rauch S.L., Savage C.R., O'Sullivan R.L., et al. Phenomenological differences appearing with repetitive behaviours in obsessive-compulsive disorder and Gilles de la Tourette's syndrome. The British Journal of Psychiatry 1997, 170:140-145.
55. Montgomery M.A., Clayton P.J., Friedhoff A.J. Psychiatric illness in Tourette syndrome patients and first-degree relatives. Advances in Neurology 1982, 35:335-339.
56. Mowla A., Khajeian A.M., Sahraian A., Chohedri A.H., Kashkoli F. Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectrum 2010, pii: Mowla. [Epub ahead of print].
57. Mundo E., Rouillon F., Figuera M.L., Stigler M. Fluvoxamine in obsessive-compulsive disorder: Similar efficacy but superior tolerability in comparison with clomipramine. Human Psychopharmacology 2001, 16(6):461-468.
58. Muscatello M.R., Bruno A., Pandolfo G., Micò U., Scimeca G., Romeo V.M., et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 2011, 31(2):174-179.
59. National Institute for Health Clinical Excellence (NICE) Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. NICE clinical guidelines, No. 31 2006, British Psychological Society, Leicester (UK). http://http:www.nice.org.uk.
60. Nee L.E., Polinsky R.J., Ebert M.H. Tourette syndrome: Clinical and family studies. Advances in Neurology 1982, 35:291-295.
61. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry 2008, 63(12):1118-1126.
62. Ohta M., Kano Y. Clinical characteristics of adult patients with tics and/or Tourette's syndrome. Brain and Development 2003, 25(Suppl.1):S32-S36.
63. O'Kearney R.T., Anstey K., von Sanden C., Hunt A. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder in children and adolescents. Cochrane Database of Systematic Reviews 2006, (4), CD004856. 10.1002/14651858.CD004856.pub2.
64. Pallanti S., Hollander E., Bienstock C., Koran L., Leckman J., Marazziti D., et al. Treatment non-response in OCD: Methodological issues and operational definitions. The International Journal of Neuropsychopharmacology 2002, 5(2):181-191.
65. Pampaloni I., Sivakumaran T., Hawley C.J., Al Allaq A., Farrow J., Nelson S., et al. High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey. Journal of Clinical Psychopharmacology 2010, 24(10):1439-1445.
66. Pediatric OCD Treatment Study (POTS) Team Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. The Journal of the American Medical Association 2004, 292(16):1969-1976.
67. Petter T., Richter M.A., Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. Journal of Clinical Psychiatry 1998, 59(9):456-459.
68. Pisani F., Oteri G., Costa C., Di Raimondo G., Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Safety 2002, 25(2):91-110.
69. Pitman R.K., Green R.C., Jenike M.A., Mesulam M.M. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. American Journal of Psychiatry 1987, 144:1166-1171.
70. Robertson M.M. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000, 123(3):425-462.
71. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. European Child and Adolescent Psychiatry 2011, 20(4):173-196.
72. Rojas-Corrales M.O., Gibert-Rahola J., Mico J.A. Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology 2007, 190(2):221-231.
73. Rosa-Alcázar A.I., Sánchez-Meca J., Gómez-Conesa A., Marín-Martínez F. Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clinical Psychology Review 2008, 28(8):1310-1325.
74. Ruffini C., Locatelli M., Lucca A., Benedetti F., Insacco C., Smeraldi E. Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: A controlled investigation. Primary Care Companion to The Journal of Clinical Psychiatry 2009, 11(5):226-230.
75. Scahill L., Erenberg G., Berlin C.M., Budman C., Coffey B.J., Jankovic J., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006, 3(2):192-206.
76. Schruers K., Koning K., Luermans J., Haack M.J., Griez E. Obsessive-compulsive disorder: A critical review of therapeutic perspectives. Acta Psychiatrica Scandinavica 2005, 111:261-271.
77. Selvi Y., Atli A., Aydin A., Besiroglu L., Ozdemir P., Ozdemir O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: A single-blind, randomised study. Human Psychopharmacology 2011, 26(1):51-57.
78. Shapira N.A., Ward H.E., Mandoki M., Murphy T.K., Yang M.C., Blier P., et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry 2004, 55(5):553-555.
79. Singer H.S. Treatment of tics and Tourette Syndrome. Current Treatment Options in Neurology 2010, 12(6):539-561.
80. Soomro G.M., Altman D., Rajagopal S., Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database of Systematic Reviews 2008, 23(1). CD001765. 10.1002/14651858.CD001765.pub3.
81. Stewart S.E., Jenike E.A., Hezel D.M., Stack D.E., Dodman N.H., Shuster L., et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 2010, 30(1):34-39.
82. Storch E.A., Merlo L.J., Bengtson M., Murphy T.K., Lewis M.H., Yang M.C., et al. D-cycloserine does not enhance exposure-relapse prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology 2007, 22:230-237.
83. Storch E.A., Murphy T.K., Goodman W.K., Geffken G.R., Lewin A.B., Henin A., et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry 2010, 68(11):1073-1076.
84. Valderhaug L., Gotestam P. An open clinical trial of cognitive-behavior therapy in children and adolescents with obsessive-compulsive disorder administered in regular outpatient clinics. Behaviour Research and Therapy 2007, 45:577-589.
85. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 2008, 165(3):335-341.
86. Worbe Y., Mallet L., Golmard J.L., Béhar C., Durif F., Jalenques I., et al. Repetitive behaviours in patients with Gilles de la Tourette syndrome: Tics, compulsions, or both?. PLoS One 2010, 5(9):e12959.
87. Zohar A.H., Pauls D.L., Ratzoni G., Apter A., Dycian A., Binder M., et al. Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. American Journal of Psychiatry 1997, 154(2):274-276.